Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice. 10 large her at $7. Follow VWAP
NVAX: Even Global REUTERS can barely handle the EXPANSIVE news still coming-out!! (More just out, below!!)
"BRIEF-Novavax Exec Says Now Anticipate Data Readouts For Both Novavax's Combination Covid-Flu Shot And Standalone Flu Vaccine In Mid 2025"
Same here. 17,150 shares at average cost of $5.17. The partnership announced today negates all of Shah's concerns. I'm revising my votes.
NVAX: This news was SPLATTERED across the entire Planet today, by every conceivable Global News Service. A FRENCH Firm partnership, bringing-in the entire European Union interest here. Then toss-in the USA, Canada, & Western Hemisphere, to boot. Not even to mention monster ASIA & the British Commonwealth. Talk about a potential, a REAL, a COLLOSAL health care MARKET PLACE!!! (And a stock PRICE this incredibly CHEAP???!!! Are you frickin' kidding me???)
thanks for the news.... good news at last... I'm in profit here... love the colour green....
NVAX: This news today goes far, far, BEYOND a simple Covid vaccine deal, Folks!!! Call me straight-up BONKERS, if you like, but this could very well become the Wall Street EXPLOSION of this frickin' YEAR 2024!!!
"Oh, Harry, what in God's name was THAT???!!! --- Fret not, Honey, it was just our NVAX stock investment taking-off on Wall Street today."
//////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////
NVAX: Notwithstanding shares count, shorting, float, inter alia, this puppy could nonetheless be a 10-bagger today, from yesterday's Close. (If I prove to be pathetically STUPID in my prognostication here, well, you can see ME, below, fully admitting just 15-minutes ago my overall Wall Street 'acumen', generally.)
CONGRAT$ ON THAT CALL
Major Developments
5/10/2024, 6:06:45 AMLicensing deal with Sanofi, $500m upfront and $700m for development.
https://dilutiontracker.com/app/search/NVAX
Novavax Soars on $1.2 Billion Sanofi Vaccine Licensing Deal
https://finance.yahoo.com/news/sanofi-inks-1-2-billion-082615895.html
JUST IN: Huge news from #Novavax ( $NVAX) as they announce a game-changing $1.4 billion deal with Sanofi ( $SNY) 🚀🔬
— Antonio Santiago (@awsan) May 10, 2024
💸 Partnership Perks:
Sanofi to invest $500M upfront, promising another $700M for hitting key milestones. Plus, an additional $200M to adopt Novavax’s Matrix-M… pic.twitter.com/MpqMqePkcd
Doesn’t look like at 7:45
Went up too high too fast
33% short in Finviz on 130m float. That’s a lot shares
imo...have you guys tried the new hand sanitizer...? .....talk about delicious~ NVAX
NVAX
IHuser
NVAX
Novavax Inc
5.1192
-0.0108 (-0.21%)
Volume: 4,050,875
Day Range: 4.98 - 5.2187
Last Trade Time: 6:11:12 PM EDT
Delayed by 15 minutes
yes, sold a few for a good little profit thank goodness then the sell off today. Grabbed a few during the melee. Looking good for this year IMO.
ascending pennant,cup and handle forming,this could be the make or break moment here,stop loss set 5.18(my in),its been steady distribution since hod,not looking good with vol fading also,no vol surges either,beating shorts is 1 in a million
weekly,monthly charts bullish,currently higher lows and highs,52M shares have to be covered in 8.7 days(they have to cover some time,but will they,dang mm/bank criminals)
Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights on February 28, 2024
https://ir.novavax.com/press-releases/2024-02-20-Novavax-to-Host-Conference-Call-to-Discuss-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Operational-Highlights-on-February-28,-2024
Schedule 13G issued for Morgan Stanley 6.2% ownership (7.3M) shares of NVAX.
SEC Filing
New Phase 3 Trial Data Confirm the Uniquely High Efficacy and Good Safety Profile of the R21/Matrix-M™ Malaria Vaccine in African Children
SERUM INSTITUTE OF INDIA PVT. LTD. — February 1, 2024
https://www.seruminstitute.com/press_release_sii_010224.php
• Investigators immunised over 4800 young children in a trial in Burkina Faso, Kenya, Mali and Tanzania and found on average 78% efficacy in the 5–17-month age group over the first year
• To date 25 million doses manufactured and ready for roll-out by The Serum Institute of India (SII) in the next three to four months
Phase 3 Trial data results of The R21/Matrix-M™ vaccine developed by Oxford University and Serum Institute of India Pvt Ltd, leveraging Novavax’s Matrix-M™ adjuvant has confirmed high efficacy and supported regulatory approvals and licensure in several African countries. The R21/Matrix-M™ vaccine was designed in 2011 as a potential improvement on the RTS, S/AS01 malaria vaccine designed in the 1980s. A phase II trial in Burkina Faso, reporting in 2021, was the first to show that R21/Matrix-M™ could reach the WHO-specified target of 75% efficacy in African children. Recent WHO endorsement will lead to the initial rollout of R21/Matrix-M™ in the coming months. The new results are published in The Lancet today.
The trial investigators immunised over 4800 young children in a trial in Burkina Faso, Kenya, Mali and Tanzania and found on average 78% vaccine efficacy over the first year of follow-up across all sites in the 5-17-month-old age group, the age range group which is studied for most malaria vaccines. Efficacy over this period was broadly similar across sites and in different transmission settings. Safety data from the trial have been reassuring with no serious adverse events linked to immunisation. No other vaccine has reported over 55% efficacy in the same age group. A booster dose at a year maintained good efficacy over the following 6-12 months. The vaccine also reduced infection rates in children measured at 12 and 18 months after vaccination suggesting a potentially beneficial effect in reducing malaria transmission.
R21/Matrix-M™ vaccine was well tolerated, with injection site pain and fever as the most frequent adverse events. Number of adverse events of special interest and serious adverse events did not significantly differ between the vaccine groups. There were no treatment-related deaths.
Malaria is the largest cause of death in young African children with over 600,000 deaths globally each year. Two vaccines have recently achieved and completed World Health Organization (WHO) prequalification and initial deployments are starting early this year.
Professor Adrian Hill, chief investigator of the R21/Matrix-M™ phase 3 trial said "The continued high efficacy of this new vaccine in field trials is very encouraging, and consistent with the high efficacy and excellent durability observed in a smaller four-year phase IIb trial. These data support an important role for the unique high-density nanoparticle display, of the conserved repeat region of the malaria parasite circumsporozoite protein, a feature in the design of the R21 vaccine, in providing such high vaccine efficacy and, thereby, an important new tool for malaria control".
Significantly increased immune responses to the R21/Matrix-M™ vaccine and slightly higher vaccine efficacy were observed in 5-17-month-olds compared to 18-36-month-olds malaria vaccines, supporting planned vaccine deployment initially from 5 months of age in young African children.
The vaccine is licensed to the Serum Institute of India (SII), the world’s largest vaccine manufacturer and a long-term partner of the University of Oxford. This is critical because vaccinating those at high risk of malaria will be important in stemming the spread of the disease, as well as protecting the vaccinated. Matrix-M™ adjuvant is manufactured by Novavax AB and provided to Serum Institute of India for formulation into the final vaccine drug product.
Adar Poonawalla, CEO, Serum Institute of India, said: "The Lancet study on R21/Matrix-M™ Phase 3 trials mark a significant advancement in our battle against this global threat. Our collaboration with the University of Oxford has been instrumental in developing the R21/Matrix-M™ malaria vaccine. We are dedicated to making this vaccine available, especially in Africa, where malaria poses a substantial threat to millions of lives, bringing us closer to a malaria-free world".
Professor Alassane Dicko, Principal Investigator in Mali of the R21/Matrix-M™ vaccine, said: "It has been very exciting to generate high efficacy data with the new R21/Matrix-M™ vaccine so quickly. I predict that this vaccine should be very impactful in preventing malaria deaths in African children".
John C Jacobs, CEO of Novavax commented "Approximately 1,300 children die from malaria every day, a staggering statistic for a preventable disease. The R21/Matrix-M™ Phase 3 efficacy data published in The Lancet reinforce the potential of R21/Matrix-M™ vaccine to protect children against this disease. We are proud of the role of Novavax's patented saponin-based Matrix-M™ adjuvant, which has been demonstrated to enhance the immune response, in the outcome of this clinical trial and are eager to see the realized impact of the vaccine when it is rolled out globally".
NVAX
Novavax Inc
4.03
0.00 (0.00%)
Volume: 7,622,424
Day Range: 3.95 - 4.24
Last Trade Time: 4:05:04 PM EST
Delayed by 15 minutes
Novavax Stock May Soar 379% — The Motley Fool
https://www.fool.com/investing/2024/01/23/novavax-may-soar-379-wall-street-says/
Novavax: Implied upside of 600%
The comeback story of the year, at least based on the price target of one Wall Street analyst, may be biotech stock Novavax (NVAX 0.62%). Despite tumbling more than 98% from its all-time high, H.C. Wainwright analyst Vernon Bernardino foresees shares of Novavax catapulting to $35. This would represent a 600% increase from the $5 shares closed at on Jan. 5.
Perhaps the biggest pendulum swing for Novavax is pending arbitration concerning orders for its COVID-19 vaccine with Gavi, a nongovernmental global vaccine organization. Gavi is seeking $700 million following the cancellation of a contract with Novavax for 350 million doses of its COVID-19 vaccine. If Novavax owes nothing, its financial foundation would be greatly improved. Meanwhile, if it has to pay $700 million to Gavi, its ability to continue as a solvent company may come into question.
Cost-cutting is another big catalyst in 2024 for Novavax. The company practically halved its operating expenses through the first nine months of 2023 -- a $950 million reduction when compared to the comparable period in 2022 -- and has plans to slash another $300 million in full-year costs in the new year. If Novavax can meet these aggressive cost-cutting goals, it should meaningfully reduce its rate of cash burn.
The other wild card here is figuring out what happens with COVID-19 vaccine demand. Novavax used traditional methods to develop a protein-based vaccine, which is markedly different than the messenger-RNA vaccines developed by Moderna and Pfizer/BioNTech. If Novavax were to see stronger demand for its COVID-19 vaccine, or gather momentum as it kicks off late-stage studies for a combination vaccine (influenza and COVID-19), it's possible shares could enjoy significant upside in the new year. While I'm not nearly as bullish on Novavax as Bernardino, a triple-digit gain could be in the cards in 2024 if things fall Novavax's way.
Full transcript of Novavax at 42nd J.P. Morgan Healthcare Conference available at Seeking Alpha.
https://seekingalpha.com/article/4661979-novavax-inc-nvax-ceo-john-jacobs-presents-jpmorgan-42nd-annual-healthcare-conference
Novavax: Creating tomorrow’s vaccines today
pharmaphorum
January 10, 2024
https://pharmaphorum.com/rd/novavax-creating-tomorrows-vaccines-today
Back in November 2023, pharmaphorum travelled to Uppsala, Sweden, for a Novavax press conference, the company celebrating a decade of doing what it does best: vaccines. From COVID-19 to malaria, Novavax focuses solely on developing vaccines against some of the world’s most serious infectious threats. What sets it apart, though, is that its vaccines are protein-based.
Founded in 1987 in the US, Gale Smith – VP of vaccine development at Novavax – invented the technique of using insect cells for producing recombinant protein vaccines. A further milestone came in 1998 in Uppsala, with the development of adjuvants for veterinary use and for humans after that. By 2013, European Novavax AB was acquired by the US Novavax Inc, combining the two techniques of recombinant proteins and S-based adjuvants, Magnus Savenhed, managing director of Novavax AB, told journalists.
Creating immunological memory without causing disease
Before a tour of the facility, Dirk Poelaert, MD and senior director of medical affairs in Europe for Novavax, who has worked in vaccines for 20 years or so, explained that protein-based vaccines work, very simply, by protecting humans by triggering the immune system to produce antibodies against a specific pathogen, making a person sick and mimicking nature by providing an antigen. “In short, vaccines create immunological memory without causing disease,” he said.
Nonetheless, recombinant protein vaccines often need an adjuvant, or a substance that increases or modulates the immune response to a vaccine. This is why the Novavax vaccine platform comprises a recombinant protein particle plus Matrix-M adjuvant, which is manufactured in Uppsala itself.
Poelaert described how a recombinant protein particle has a native 3-dimensional conformation, with truncated S. frugiperda glycans and a particulate structure that facilitates antigen presentation and processing. Meanwhile, the Matrix-M adjuvant induces robust neutralising antibodies and induces polyfunctional CD4+TH1 lymphocytes (T helper cells). Formulation is in a nanoparticle with the recombinant protein particle.
Protein-based vaccines and recombinant expression systems
What might not be realised is that protein-based vaccines have existed for many decades for the prophylaxis of bacterial and viral diseases. They are indicated across the spectrum of infants, children, and adults, and have a favourable safety profile with well-known benefits. Nevertheless, originally the proteins used in vaccines were purified exclusively from cultures of an infectious agent, while today, specific immunogenic proteins can be generated through recombinant expression systems, said Poelaert.
Novavax takes the RNA sequence that codes and then incorporates into a baculovirus that can only infect insects, not humans. It uses the Sf9 cell, an ovary cell of an army moth, and the baculovirus enters the insect cell, including its nucleus, wherein it releases its genetic material. The machinery of this cell will produce the original protein had in mind, which then rises to the surface of the cell, where it is harvested and put into contact with the core, the polysorbate 80, the emulsifiers, and go towards a full vaccine.
Global public health: The malaria case
In terms of the global context, also in attendance was Dr Ole Olesen, PhD, executive director of the European Vaccine Initiative (EVI). EVI is an independent, non-profit research organisation that supports the development of safe and effective vaccines for global health – including affordability. It supports vaccine R&D through pre-clinical and clinical development, having helped with over 40 vaccine formulations. Dr Olesen noted how infectious diseases are often forgotten in the Western world.
“However, in the poorer parts of the world, infectious diseases are still a huge problem,” he reminded journalists. “More than 10 million people each year die from such. If one looks specifically at the malaria example, there are almost 250 million cases per year […] As a global community, this needs to be addressed.” Indeed, in 2022, there were 608,000 deaths from malaria across 85 countries worldwide.
As of December 2023, though, Novavax’s R21/Matrix-M malaria vaccine received pre-qualification from the World Health Organization (WHO), to prevent malarial disease in children caused by the P. falciparum parasite in endemic areas, allowing United Nations (UN) agencies to procure the vaccine in eligible countries and enable rollout of the vaccine.
The power of partnerships (and adjuvants)
Developed by the University of Oxford and the Serum Institute of India using Novavax’ saponin-based Matrix-M adjuvant – which helps stimulate immune responses to the vaccine – the R21/Matrix-M malaria vaccine has gained authorisation for use in children in Burkina Faso, Ghana, and Nigeria. Meanwhile, R21/Matrix-M is one of several ongoing collaborations involving Novavax’s adjuvant technology, with additional research in malaria and other infectious diseases in both humans and animals.
“In an ideal world, the disease burden should match the amount of research investment going into solving them,” he continued. “Malaria has, though, an enormous discrepancy between the disease burden and the amount of global investment. It costs over $500 million to develop a new vaccine, though; it is expensive, and this is a conservative figure. Some other projections are four or five times that amount. Clearly, it’s an expensive business. Additionally, there is a complexity to the disease itself […], and malaria has taken almost 150 years to get to the point now where there is a potential vaccine.”
“The immune system is like a sleeping dog,” Dr Olesen said. “Non-vaccinated, [it] remains asleep; immunised with active ingredient only, it remains in semi-dormancy. It is only when immunised with an active ingredient adjuvant that the dog is alive and kicking (and barking and biting, as one’s immune system should in the face of the infection). Companies like Novavax, with unique technologies like the Matrix-M adjuvant (the difference between a vaccine that works and doesn’t) need to engage in solving global health problems, a critical mass coming together, [and] the R21 malaria vaccine is an example of this, indeed.”
The pandemic period
During the pandemic, Novavax was operating under a joint contract with the EU Commission, delivering the vaccine through that (which came to an end at the close of 2023) to different governments around the world. Now, the company has initiated a transition into a “new and normal commercial situation in Europe,” Jorgen Persson, VP of market access and customer engagement, told journalists.
In different countries, governments are still considering their management of the vaccine post-pandemic, and so Novavax is in discussions with those governments. There is, Persson said, a dialogue from the perspective of delivering an updated vaccine that covers the needs of the space as it is now. The vaccine is approved in over 40 countries and recommended by the WHO. Well-positioned with proven technology, pipeline assets, commercial execution, and a focus on corporate development, Novavax’s platform seems to stand it in good stead for its desired future.
The value of vaccines
Previously, pharmaphorum had spoken with Alvar Paz, general manager for Europe at Novavax, and Silvia Taylor, executive vice president and chief corporate affairs and advocacy officer for Novavax, at the Economist Impact Future of Health Europe Summit in London. Taylor later partook in a fireside chat at the conference with Michael Guterbock on the value and power of vaccines.
Taylor joined Novavax in June 2020, right as the pandemic was hitting. In the time since, she’s helped to build the company from a very small, development-stage company to a global commercial organisation with authorisations around the world and commercial operations and manufacturing in Europe. Paz, meanwhile, joined Novavax two years later, in June 2022.
When it comes to public health, education is key, insisted Taylor: the availability, the choice, the options of vaccines. It's about trust. And Novavax hopes to be among the first companies to commercialise a combination vaccine (COVID and influenza).
“That's almost the holy grail, right?” she said. “If you think about it, it's two seasonal vaccines given in one jab. I think the convenience and the adherence to vaccination will greatly improve when you do combination products like this, but that is a few years away. We're still in phase two, and so I think we've got a couple of years more of our clinical development before we go to that.”
“I think the uniqueness of what Novavax is bringing to market is that we're the only protein-based option,” she continued. “It has advantages in terms of not needing to be frozen, it's refrigerator stable. I think, speaking to demand, you've got the consumer demand, you've also got the healthcare providers who have to administer. It's a really attractive profile.”
Remembering that COVID isn’t ‘done’
In October 2023, Novavax was given the go-ahead by regulators in the US for an updated version of its COVID-19 vaccine, which targets the XBB.1.5 variant of the coronavirus.
“COVID isn't done with us. It continues [and] it continues to change,” explained Taylor. “It continues to be something that we see a need for. In fact, in markets like the US, the recommendations are even broader than what we see in Europe in terms of giving accessibility to everybody in the market to get vaccinated as they choose. We think that's a great model. It's not the way it is here in Europe.”
“When you're talking about infectious diseases, you're not just vaccinating yourself for yourself, you're doing it for your community, you're doing it for your country,” she added. “You literally see things spreading. What we say about, "Nobody is safe until everybody is safe," is very, very much true.”
“We should be grateful to the mRNA vaccine, which is a pandemic vaccine, but ours is the endemic vaccine,” Paz noted. “A protein-based vaccine has proven the features that much better fit an endemic situation, [including] supply stability, temperature stability, even the product features themselves: efficacy, longer duration and durability, and safety profile.”
The press conference in Sweden might have been missing the Scandinavian summer light, but it appears that the light of vaccine-protective hope is burning brightly at Novavax, from COVID to malaria, and beyond.
Virtual webcast link to 42nd Annual J.P. Morgan Healthcare Conference NVAX. Definitely worth a listen. Bright future for Novavax with clear focus on cutting unnecessary expenses and growing business.
https://ir.novavax.com/events?year=2024&month=1#nav
Click on Virtual webcast link, which redirects you to J.P. Morgan website. Enter info to access webcast. Recommend opt-out of info sharing, or enter made-up data (for those who prefer not to have to provide personal info) as no email confirmation is required to access the webcast.
Novavax: Implied upside of 600% - The Motley Fool
3 Turnaround Stocks With 151% to 600% Upside in 2024, According to Select Wall Street Analysts
Sean Williams, The Motley Fool
Tue, January 9, 2024, 5:21 AM EST
https://finance.yahoo.com/news/3-turnaround-stocks-151-600-102100466.html
Novavax: Implied upside of 600%
The comeback story of the year, at least based on the price target of one Wall Street analyst, may be biotech stock Novavax (NASDAQ: NVAX). Despite tumbling more than 98% from its all-time high, H.C. Wainwright analyst Vernon Bernardino foresees shares of Novavax catapulting to $35. This would represent a 600% increase from the $5 shares closed at on Jan. 5.
Perhaps the biggest pendulum swing for Novavax is pending arbitration concerning orders for its COVID-19 vaccine with Gavi, a nongovernmental global vaccine organization. Gavi is seeking $700 million following the cancellation of a contract with Novavax for 350 million doses of its COVID-19 vaccine.
If Novavax owes nothing, its financial foundation would be greatly improved. Meanwhile, if it has to pay $700 million to Gavi, its ability to continue as a solvent company may come into question.
Cost-cutting is another big catalyst in 2024 for Novavax. The company practically halved its operating expenses through the first nine months of 2023 -- a $950 million reduction when compared to the comparable period in 2022 -- and has plans to slash another $300 million in full-year costs in the new year. If Novavax can meet these aggressive cost-cutting goals, it should meaningfully reduce its rate of cash burn.
The other wild card here is figuring out what happens with COVID-19 vaccine demand. Novavax used traditional methods to develop a protein-based vaccine, which is markedly different than the messenger-RNA vaccines developed by Moderna and Pfizer/BioNTech. If Novavax were to see stronger demand for its COVID-19 vaccine, or gather momentum as it kicks off late-stage studies for a combination vaccine (influenza and COVID-19), it's possible shares could enjoy significant upside in the new year.
While I'm not nearly as bullish on Novavax as Bernardino, a triple-digit gain could be in the cards in 2024 if things fall Novavax's way.
***Sniff sniff***
Smells like short squeeze
$NVAX
Novavax Investor Presentation for J.P. Morgan Healthcare Conference
Filed today as part of 8-K SEC filing.
LINK: Presentation
NEWS: Novavax's Updated COVID-19 Vaccine Now Authorized in Canada
https://ir.novavax.com/press-releases/2023-12-05-Novavaxs-Updated-COVID-19-Vaccine-Now-Authorized-in-Canada
December 5, 2023
• Novavax's updated protein-based non-mRNA COVID-19 vaccine will be available in Canada for individuals aged 12 and older in the coming days
GAITHERSBURG, Md., Dec. 5, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Health Canada has granted expanded authorization for Nuvaxovid™ XBB.1.5 Vaccine (Recombinant protein, Adjuvanted) (NVX-CoV2601) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged 12 and older. The Public Health Agency of Canada's National Advisory Committee on Immunization recommended XBB COVID-19 vaccines that target more recent, immune-evasive variants of the virus.1
"Today's expanded authorization will support the Canadian government's strong commitment to provide its citizens with effective options, such as our protein-based non-mRNA vaccine, in the campaign against currently circulating COVID-19 variants," said John C. Jacobs, President and Chief Executive Officer, Novavax. "We look forward to helping to protect Canadians in time for the upcoming holiday season and, pending vaccine batch release, have doses in market for access across the country."
The expanded authorization was based on non-clinical data showing that Novavax's COVID-19 vaccine induced functional immune responses against XBB.1.5, XBB.1.16 and XBB.2.3 variants. Additional non-clinical data demonstrated that Novavax's vaccine induced neutralizing antibody responses to subvariants BA.2.86, EG.5.1, FL.1.5.1 and XBB.1.16.6 as well as CD4+ polyfunctional cellular (T-cell) responses against EG.5.1 and XBB.1.16.6. These data indicate Novavax's vaccine can stimulate both arms of the immune system and may induce a broad response against currently circulating variants.2,3
In clinical trials, the most common adverse reactions associated with Novavax's prototype COVID-19 vaccine (NVX-CoV2373) included headache, nausea or vomiting, muscle pain, joint pain, injection site tenderness, injection site pain, fatigue and malaise.
Novavax's updated COVID-19 vaccine is also authorized in the U.S., the European Union and by the WHO, and is under review in other markets.
World Health Organization (WHO) recently recommended a malaria vaccine that uses Novavax's proprietary Matrix-M adjuvant technology and will be rolled out next year,
Followers
|
341
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
8595
|
Created
|
06/19/03
|
Type
|
Free
|
Moderators mick JoeForkeyBolo |
Novavax, Inc. is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases.
Using innovative proprietary recombinant nanoparticle vaccine technology,
we produce vaccine candidates to efficiently and effectively respond to both known and emerging disease threats. More...
INVESTORS
Novavax is traded on the Nasdaq Stock Market under the symbol NVAX and is dedicated to developing novel vaccines to address infectious disease. More...
*DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |